- About Us
- Our Clients
- Practice Areas
- Asia Pacific Law
- Bankruptcy, Insolvency & Restructuring
- Competition Law
- Corporate & Commercial
- Criminal & Extradition
- Environmental, Energy & Natural Resources
- Family Law
- First Nations & Aboriginal Law
- Intellectual Property
- Immigration Law
- International Trade Law
- Labour & Employment Law
- Litigation & Dispute Resolution
- Maritime Law
- Municipal Law
- Real Estate Law
- Taxation Law
- Wealth Management
- Wine Law
- Our People
- Global Services
- Students
- Careers
- News
- Contact Us
News
23 July 2009
James Hatton Appears in Lexpert Magazine’s Big Deals Section
On April 8, 2009, Cardiome Pharma Corp. of Vancouver signed a licensing deal with Merck & Co., Inc., worth up to $1 billion if all milestones are met, which would make it the largest Canadian lifesciences licensing deal in history. Merck will pay US$60 million up front and provide a $100 million line of credit with an additional $300 million in clinical milestone payments and $340 million in commercial milestones, along with tiered royalties for the commercialization of the drug vernakalant, which is being investigated as a treatment for atrial fibrillation, an abnormal heart rhythm.
Farris Partner James Hatton and Barbara Kosacz of Cooley Godward Kronish acted for Cardiome, and Anke Kramer, in-house counsel, represented Merck.
News
E-Newsletter
Sign up for our Email Newsletter to receive regular Farris updates: